All Type of News
Health ministry mulls reorganization plan
The Ministry of Health and Welfare is formulating a plan for the major realignment of its existing organization in an effort to prepare for the possible merging of the Ministry of Gender Equality and Family into the M...
Bioequivalence testing data to be submitted in product license
Drug makers, who intend to apply for the product license for three medicines, will have to submit the bioequivalence data to the Korea Food and Drug Administration (KFDA). The KFDA said the notification is designed to...
Government to ban dual prescription of same medicines at same hospitals
From this April, doctors will not prescribe some identical drugs to a same patient prior to a week, according to the Ministry of Health and Welfare.
Under the newly revised regulation, the patient cannot receive a ...
Ethics management seminar to be held
A local seminar will be held on February 12 at Sofitel Ambassador Hetel in Seoul with participants from the government and pharmaceutical circles.
The seminar, jointly organized by theKorea Pharmaceutcal Manufactur...
Huons ties up with Alcon Korea
Huons Co. has clinched a strategic alliance with Alcon Korea as part of its efforts to tap the global market, with its new preservative-free artificial tears eye product, KYNEX.
Under the recently executed agreemen...
Is incoming government's drug policy good signal to pharmaceutical industry? (second part)
The next government will unlikely promote a friendlier business environment over the current drug pricing policy, as president-elect Lee Myung-bak vowed to slash the government' expenditure by 10 percent.
If this i...
Court ruling due over new pricing drug policy
The Seoul Administration Court says it will make a final ruling on February 27 over the so-called positive list system in terms of the constitutional violation.
The Korea Pharmaceutical Manufacturers Association (K...
Plavix generic makers agonize over market entry
Korea's 17 generic makers won the right to market Plavix (clopidogrel bisulfate) in a recent patent lawsuit, several drug makers who will join the lucrative market with their newly modified medicines are keen on the l...
Ginkgo biloba preparations to be non-reimbursable
The government says that from May, medicines containing gingko biloba will be deleted from the national health insurance list, after a two-month grace period, according to the Ministry of Health and Welfare.
Under ...
Yungjin launches Servier's new antihypertensive agent
Yungjin Pharm says it has introduced Acertil Plus tablets to strengthen its presence in the domestic hypertension market.
Developed by France based Servier Co., Acertil Plus is an antihypertensive therapy involving...
